Abstract: The present invention relates to the processes for the preparation of substituted pyrazole derivatives of formula (I), (II), (III), (IV), (IV-a) (V), (VII), which are useful as intermediates in anthranilamide insecticides production. In addition, the present invention is directed to a method for the preparation of anthranilamides of formula (VIII) using substituted pyrazole derivatives of formula (I), (III), (IV), (V), (VII). Furthermore, the present invention is directed to substituted halo-pyrazole compounds of formula (III), (IV) and (V), wherein X is halogen and R7 is hydrogen, C1-C4 alkyl.

Abstract: The present subject matter provides a safe alternative for producing an important intermediate useful for preparing the herbicide glufosinate, without need for chlorine components in the manufacturing process. In particular, a process for preparing alkyl phosphinic aid alkyl ester is provided, including the step of alkylating alkyl phosphinic acid ester in a non-polar solvent in the same apparatus as used to first produce the alkyl phosphinic acid ester, and without isolating the alkyl phosphinic acid ester before the alkylation step is conducted. More specifically, a process is presented for preparing methyl phosphinic acid butyl ester, by alkylating butyl phosphinic acid ester in a non-polar solvent, in the same apparatus as used previously to first produce the butyl phosphinic acid ester and without isolating the butylphosphinic acid ester before alkylation.

Abstract: It is an object of the present invention to provide a novel and advantageous process for commercially preparing quinmerac.

Abstract: A method is disclosed for preparing pyrazole derivative 3-bromo-5-methyl-1-H-pyrazole-N-2-chloropyridine (compound of Formula I) by reacting of a compound of Formula II with halogen substituted pyridine optionally in the presence of base and organic solvent or by decarboxylation of pyrazole carboxylic acid of Formula XI in the presence of acid. In addition, provided a method of preparation of synthetic precursors of Formula II, Formula IV, Formula V, Formula VI, Formula XI, and a method of preparing a compound of Formula VII comprising reacting a compound of Formula I with an oxidant optionally in the presence of a catalyst. Also disclosed a compound of Formula I as useful synthetic precursor for preparation of anthranilamide of Formula VIII.

Abstract: It is an object of the present invention to provide a novel and advantageous process for commercially preparing quinmerac.

Abstract: The present invention provides a process for preparing a compound of the formula (I): wherein each occurrence of R1 is a C1-C4 alkyl; and R2 is C1-C4 alkyl.

Abstract: A process for preparing, 1,1,3-Trioxo-1,2-benzothiazole-6-carboxamide of formula (I) comprising: reacting 2-chloro-sulfonyl-terephthalic acid dialkyl ester of formula (II) with ammonia (N H3) or ammonium containing-salt; wherein R represents a branched or non-branched C1-C12 alkyl.

Abstract: The present subject matter provides a safe alternative for producing an important intermediate useful for preparing the herbicide glufosinate, without need for chlorine components in the manufacturing process. In particular, a process for preparing alkyl phosphinic aid alkyl ester is provided, including the step of alkylating alkyl phosphinic acid ester in a non-polar solvent in the same apparatus as used to first produce the alkyl phosphinic acid ester, and without isolating the alkyl phosphinic acid ester before the alkylation step is conducted. More specifically, a process is presented for preparing methyl phosphinic acid butyl ester, by alkylating butyl phosphinic acid ester in a non-polar solvent, in the same apparatus as used previously to first produce the butyl phosphinic acid ester and without isolating the butylphosphinic acid ester before alkylation.

Abstract: The present invention provides a process for preparing a compound of the formula (I): wherein each occurrence of R1 is a C1-C4 alkyl; and R2 is C1-C4 alkyl.

Abstract: A process for preparing, 1,1,3-Trioxo-1,2-benzothiazole-6-carboxamide of formula (I) comprising: reacting 2-chloro-sulfonyl-terephthalic acid dialkyl ester of formula (II) with ammonia (N H3) or ammonium containing-salt; wherein R represents a branched or non-branched C1-C12 alkyl.

Abstract: The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.

Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.

Abstract: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.

Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase signaling cascade.

Abstract: The invention relates to pyrazoline substituted compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.

Abstract: The invention relates to sulfonamide compounds and methods for activating PKM2. The compounds and methods are useful in treating or preventing a disease or disorder selected from cancer, cell proliferative disorder, inflammatory disorder, metabolic disorder, and immune system disorder.

Abstract: The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.

Abstract: The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for prevention, alleviation or treatment of autoimmune neurodegenerative disorders, in particular multiple sclerosis and associated symptoms. Methods of the invention are useful when the active ingredient is administered alone or in combination with existing therapeutic modalities. The compositions are administered by oral route.

Abstract: The present invention relates to novel benzofuran compounds, to pharmaceutical compositions that include such compounds, and to methods of use thereof. Certain compounds of the invention share some pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents.

Abstract: The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic latera